UNSPSC 51343402: Amdoxovir

This classification denotes a reverse transcriptase inhibitor with the molecular formula C9H12N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 54I81H0M9C, chemically known as 2,6-diaminopurine dioxolane but generally known as amdoxovir, which bears US NIH Compound Identifier 124088. European Medicines Agency schedules Amdoxovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20547.

The term AMDOXOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). Most nations schedule amdoxovir under HS 29349990 and SITC 51579. As of Q4 2014, AMDOXOVIR remains the US FDA Preferred Term for this commodity. Amdoxovir bears US NLM identifiers UMLS ID C1528970 and NCI Concept Code C76927. SMILES: O1C(n2c3nc(nc(N)c3nc2)N)COC1CO.

UNSPSC 51343402 Amdoxovir is a Commodity code reflecting pharmaceutical products that state and local governments procure for emergency response, public health, and pharmacy benefit programs. Recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing alliances, and medical and first aid supplies for fire and rescue operations. The issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Department of Administration's MMCAP). Scope ranges from emergency pharmaceutical products supporting opioid response programs to routine medical consumables (respiratory equipment, cardiac monitoring electrodes, bandaging materials, oxygen delivery systems) and generic pharmaceutical procurement across networked wholesalers serving multiple jurisdictions.

Geographic activity centers on Florida, Texas, and Minnesota, with multistate cooperative programs extending coverage to states like Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) procuring 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription program capabilities; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies with an estimated contract value of $700,000, designated as sheltered market opportunity with 5% bid discount for certified Small Local Business Enterprises; and Minnesota MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products through authorized wholesalers with July 1, 2026 effective date.